...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

To your point, the referenced publication is dated December 11, 2020.

As for withholding information considered material, it is my opinion that this news is not material.  It is when something is proven, i.e. Phase 3 trial results, that it meets the definition of material.  JMHO

Share
New Message
Please login to post a reply